Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;70(1):3-11.
doi: 10.33073/pjm-2021-003. Epub 2021 Mar 9.

The Pathogenesis of Aspergillus fumigatus, Host Defense Mechanisms, and the Development of AFMP4 Antigen as a Vaccine

Affiliations
Review

The Pathogenesis of Aspergillus fumigatus, Host Defense Mechanisms, and the Development of AFMP4 Antigen as a Vaccine

Xiang Gu et al. Pol J Microbiol. 2021 Mar.

Abstract

Aspergillus fumigatus is one of the ubiquitous fungi with airborne conidia, which accounts for most aspergillosis cases. In immunocompetent hosts, the inhaled conidia are rapidly eliminated. However, immunocompromised or immunodeficient hosts are particularly vulnerable to most Aspergillus infections and invasive aspergillosis (IA), with mortality from 50% to 95%. Despite the improvement of antifungal drugs over the last few decades, the therapeutic effect for IA patients is still limited and does not provide significant survival benefits. The drawbacks of antifungal drugs such as side effects, antifungal drug resistance, and the high cost of antifungal drugs highlight the importance of finding novel therapeutic and preventive approaches to fight against IA. In this article, we systemically addressed the pathogenic mechanisms, defense mechanisms against A. fumigatus, the immune response, molecular aspects of host evasion, and vaccines' current development against aspergillosis, particularly those based on AFMP4 protein, which might be a promising antigen for the development of anti-A. fumigatus vaccines.

Keywords: Aspergillus fumigatus; Aspergillus fumigatus mannoprotein; vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.

Similar articles

Cited by

References

    1. Alanio A, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S. Investigating clinical issues by genotyping of medically important fungi: why and how? Clin Microbiol Rev. 2017. Jul;30(3):671–707. 10.1128/CMR.00043-16 - DOI - PMC - PubMed
    1. Almeida MC, Antunes D, Silva BMA, Rodrigues L, Mota M, Borges O, Fernandes C, Gonçalves T. Early interaction of alternaria infectoria conidia with macrophages. Mycopathologia. 2019. Jun;184(3):383–392. 10.1007/s11046-019-00339-6 - DOI - PubMed
    1. Anthoney N, Foldi I, Hidalgo A. Toll and Toll-like receptor signalling in development. Development. 2018. May 01;145(9):dev156018. 10.1242/dev.156018 - DOI - PubMed
    1. Arias M, Santiago L, Vidal-García M, Redrado S, Lanuza P, Comas L, Domingo MP, Rezusta A, Gálvez EM. Preparations for invasion: modulation of host lung immunity during pulmonary aspergillosis by gliotoxin and other fungal secondary metabolites. Front Immunol. 2018. Nov 6;9:2549. 10.3389/fimmu.2018.02549 - DOI - PMC - PubMed
    1. Barac A, Vukicevic TA, Ilic AD, Rubino S, Zugic V, Stevanovic G. Complications of chronic necrotizing pulmonary aspergillosis: review of published case reports. Rev Inst Med Trop São Paulo. 2017; 59(0):e19. 10.1590/s1678-9946201759019 - DOI - PMC - PubMed

MeSH terms